A gene editing technology has shown promising early results in treating patients with Hepatitis B. Participants in the ELIMINATE-B trial were dosed in PBGENE-HBV, developed by gene editing company Precision BioSciences, at multiple ascending dose levels. Results show PBGENE-HBV, which comprises an ARCUS-encoding mRNA encapsulated in a lipid nanoparticle… Read More
Precision BioSciences has announced positive initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level… Read More
Precision BioSciences has announced it will commence a Phase I clinical trial for its in vivo gene editing programme PBGENE-HBV, following Clinical Trial Application (CTA) approval in Moldova. PBGENE-HBV is designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B… Read More
